• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Infection and Drug Resistance >Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus
【2h】

Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus

机译：重组人乳头瘤病毒非价疫苗预防人乳头瘤病毒引起的癌症

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Human papillomavirus (HPV) types 16 and 18 cause 70% of cervical cancer cases globally. The nonavalent HPV vaccine (9vHPV) was licensed in 2014 and protects against the next five most common cancer-causing HPV types (HPV 31/33/45/52/58) after HPV 16/18. Phase III clinical studies have demonstrated high vaccine efficacy (>90%) against cervical, vulvar, and vaginal precancers caused by these additional types, and have shown comparable immunogenicity to the shared genotypes to quadrivalent HPV vaccine (4vHPV). Vaccine efficacy and antibody responses for 9vHPV are found to persist for at least five years while longer-term observational studies are ongoing to monitor long-term vaccine effectiveness. The implementation of 9vHPV has the potential to prevent up to 93% of cervical cancer cases, as well as a significant proportion of other HPV-related anogenital cancers. This review article summarizes the current evidence for 9vHPV in terms of vaccine efficacy against HPV infection and related anogenital precancers, safety, and immunogenicity, as well as discussing the potential impact of this vaccine on the cervical cancer burden globally.
机译：人类乳头瘤病毒（HPV）16和18型导致全球70％的宫颈癌病例。非价型HPV疫苗（9vHPV）于2014年获得许可，可预防HPV 16/18之后的五种最常见的致癌HPV类型（HPV 31/33/45/52/58）。 III期临床研究表明，由这些其他类型引起的针对宫颈癌，外阴癌和阴道癌的高疫苗效力（> 90％），并显示出与四价HPV疫苗（4vHPV）共有的基因型相当的免疫原性。发现9vHPV的疫苗效力和抗体反应至少持续五年，而长期的观察性研究正在进行中以监测长期的疫苗效力。 9vHPV的实施有可能预防多达93％的宫颈癌病例，以及相当一部分其他HPV相关的肛门生殖器癌症。这篇综述文章就针对HPV感染的疫苗效力和相关的生殖器前癌，安全性和免疫原性总结了9vHPV的最新证据，并讨论了该疫苗对全球子宫颈癌负担的潜在影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号